Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Guillain-Barré Syndrome (GBS) is a rare neurological condition where the immune system attacks the peripheral nerves. It has a small but established association with certain vaccines — here's what the data shows.
Guillain-Barré Syndrome causes the immune system to attack the myelin sheath surrounding peripheral nerves. Symptoms include:
GBS is most commonly triggered by infections — especially Campylobacter jejuni bacteria, influenza, cytomegalovirus, and Epstein-Barr virus. The vaccine association is much smaller than the infection association.
The most established vaccine-GBS association. Studies estimate approximately1-2 additional GBS cases per million flu vaccine doses. This was first identified during the 1976 swine flu vaccination campaign, which had a higher rate (~1 per 100,000). Modern flu vaccines have a much smaller risk.
Importantly, influenza infection itself carries a higher GBS risk than the vaccine — about 17 times higher per the CDC. So vaccination actually reduces your overall GBS risk by preventing the flu.
The J&J/Janssen COVID-19 vaccine was found to have a small increased risk of GBS, estimated at about 8 cases per million doses in the first 6 weeks. This was one factor in the CDC's preference recommendation for mRNA vaccines (Pfizer, Moderna) over J&J. J&J is no longer available in the U.S.
Studies have generally not found an increased GBS risk with mRNA COVID vaccines. The adenoviral vector mechanism in J&J appears to be the relevant factor, not COVID vaccination in general.
VAERS contains reports of GBS after various vaccines. As with all VAERS data, these are reports of temporal association — not confirmed causation. The established associations described above come from large epidemiological studies, not from VAERS alone.
GBS is on the Vaccine Injury Table, meaning that GBS occurring within a defined time window after certain vaccines is eligible for compensation through theVaccine Injury Compensation Program.
For most people, yes. The risk of GBS from vaccination is extremely small (1-2 per million) and the risk of GBS from the infections that vaccines prevent is typically higher. However, people who have had GBS within 6 weeks of a previous vaccine dose should discuss future vaccination with their neurologist.
As of mid-2026, the Guillain-Barré Syndrome vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into Guillain-Barré Syndrome vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like Guillain-Barré Syndrome has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for Guillain-Barré Syndrome vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about Guillain-Barré Syndrome vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.
As of mid-2026, the Guillain-Barré Syndrome vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into Guillain-Barré Syndrome vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like Guillain-Barré Syndrome has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for Guillain-Barré Syndrome vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about Guillain-Barré Syndrome vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.